

ASX Announcement

Medibio Limited – 4 May 2020



Medibio strengthens its IP protection Significant US Patent awarded for method and system for assessing mental state

Melbourne, Australia and Minneapolis, MN – 4 May 2021: Medibio Limited (Medibio or the Company) (ASX: MEB) (OTCPINK: MDBIF), has been awarded a patent from the US Patent and Trademark Office for the Company's "Method and System for Assessing Mental State".

The patent relates to a computer-implemented method of assessing the mental state of a subject by receiving a sequence of heartbeat data samples obtained overnight through three distinct periods: a pre-sleep, sleep, and a post-sleep period.

This patent enriches the Company's intellectual property and further strengthens its strategic protection across the Company's key commercial markets, including clinical, corporate and consumer.

The awarding of this patent is timely given that the company is currently undertaking trials to validate its medical software (MEB-001) that will identify depressive burden in patients suffering from sleep disturbance. MEB-001 consists of sleep staging algorithms (MEBsleap), overlayed by overnight heartrate and heart-rate-variability algorithms, leading to the depressive burden analysis.

The Company's pioneering efforts to establish objective methods to evaluate mental health supports help-seeking behavior and improved treatment. A significant barrier to effective care for patients suffering from depression is misdiagnosis due to subjective methodology, which has far-reaching consequences on an individual's emotional and psychological welfare and imposes significant costs upon government health budgets.

Medibio's understanding of the biology of depression, together with recent technological advances in artificial intelligence and deep learning algorithm methodology, is bringing reliable, objective, evidence-based tools within reach.

– ENDS –

This announcement is authorized for release to the market by the Board of Directors of Medibio Limited.

About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

Samantha Eng
WE Communications
+61 432 063 216
WE-AUMedibio@we-worldwide.com

Level 4, 100 Albert Road, South Melbourne, Vic 3205
Email: info@medibio.com.au | www.medibio.com.au